Johnson & Johnson (NYSE:JNJ) is considered one of the Most Undervalued High Quality Stocks to Buy According to Hedge Funds. Guggenheim analyst Vamil Divan maintained a Hold rating on JNJ with a price target of $164 on July 10. Q2 2025 earnings call is scheduled for July 16 after the company’s Q1 2025 results showed growth in sales.

The company faces a 200% tariff risk from President Trump on Pharmaceuticals, impacting investor sentiment. Johnson & Johnson operates through two segments, Innovative Medicine and MedTech. While JNJ has investment potential, some AI stocks offer greater upside potential with less downside risk in the current market.

For more insights on AI stocks and potential investment opportunities, check out our free report on the best short-term AI stock. Consider the impact of Trump-era tariffs and the onshoring trend on investment decisions. Additionally, explore other stocks that are projected to double in three years and hidden AI stocks to buy right now for future investment opportunities.

Read more at Yahoo Finance: Guggenheim Maintained a Hold Rating on Johnson & Johnson (JNJ)